- The posters will be displayed between October 26-28, 2011 at the Exhibition Area of the Harbiye Military Museum according to the following schedule:
Poster Mount Date & Time : October 26, 2011 at 08:00
Poster Remove Date & Time : October 28, 2011 at 12:30
The organization secretariat is not responsible for the posters that haven't been removed after the session.
Poster Viewing Schedule
Dates : October 26-27-28, 2011
Time : 10:45 - 11:15
Hall : Exhibition Hall
Poster discussions will take place in front of the posters. Presenters should be beside their posters during the viewing date and times and should have handouts of their poster available.
Please find the instructions of the poster presentation below, the organizers will provide suitable fixing materials during the mounting times. - Posters should be approximately 70 cm in width and 100 cm in height.
- Posters must be legible from a distance of about 1 m.
- Please indicate the title, name(s) of author(s), institutional address (es) of author(s).
- The title should be written in capital letters 2.5 cm high.
- The authors should be present by their posters at the scheduled time.
- Discussions will take place in front of the posters.
PRIZES
POSTER PRESENTATIONS
Risk Management Plans
PP001. Prescribing and Dispensing Thalidomide in Turkey: Compliance with the Thalidomide Risk Management Program (TRMP)
S. Oncel, A.N. Aslan, P. Sheehan, J. Freeman and R. Bwire
PP002. Adjudicating Equivocal Pregnancy Test Results within the Lenalidomide Risk Minimization Program in Turkey: A Case Report
B. Ozcan, A.N. Aslan, S.T. Kaehler, J. Freeman and R. Bwire
PP003. Effectiveness Assessment Survey of the Spanish Risk Management Plan for Lenalidomide
L. Brum, D. Laplaza, S.T. Kaehler, J. Freeman and R. Bwire
PP004. Herceptin_ (Trastuzumab): Risk Management Planning
S. Daniels, M. Johnston and L. Hiles
PP005. Completeness of Protocols of Post-Authorisation Safety Studies (PASS) Included in EU Risk Management Plans (EU-RMPs): Preliminary Analysis
C. Drai, A. Fourrier Reglat, P. Arlett and X. Kurz
PP006. Web-Based Prescription Guide As a Country-Specific Risk Minimization Measure: An Application from Turkey
B. Unal, S. Koseoglu, H. Oberender and S. Heaton
PP007. Analysis of Risk Minimizations Activities (RMA) for Products Approved via Centralized Procedure (CP) since 1 January 2010 to 31 March 2011
S. Baquero and E. Falco
PP008. The Drugs Monitored by TUFAM with Risk Management Plan (RMP)
Y. Kasap, D.N. Aydınkarahaliloglu, E. Aykac¸, C. Babacanoglu,G. Sagis, H. Ilbars, H. Ozbek and S. Saim
PP009. Mandatory Risk Management Plans in Argentina
I. Bignone, C.L. Santucci and P.A. Mariani
PP010. A Review of Pharmacovigilance and Risk Minimisation Measures Associated with Biosimilar Products Approved in the EU
B. Mulchrone, C. Key and W. Lee
Signal Detection
PP011. Feasibility of Conducting Data Mining for Signal Detection Using a Canadian Administrative Claims Database (RAMQ)
L. Nkeng, T. Ducruet,S. Be´land, F. Nekka,J. Lelorier and Y. Moride
PP012. Cefixime-Induced Thrombocytopenia Requiring Multiple Platelet Transfusions in Diabetic Foot
A.R. Burande, M.A. Burande and S.C. Sahni
PP013. Identifying Drugs Causing Acute Immune Thrombocytopenia: Results from the Berlin Case- Control Surveillance Study
E. Garbe, F. Andersohn, E. Bronder, A. Salama, A. Klimpel, M. Thomae, H. Schrezenmeier, M. Hildebrandt, E. Spath Schwalbe, A. Gruneisen and H. Kurtal
PP014. Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions: Comparison of DataMining of Spontaneous Reporting Databases
N. Mirosevic Skvrce, V. Macolic Sarinic,D. Krnic, S. Tomic, I. Mucalo and N. Bozina
PP015. From Signal Detection to Evaluation to Action: The Experience of Pediacel_ and Apnea
A. Pinc¸on, G. Carrigan, F. Sillan, A. Khromava and C. Pierfitte
PP016. The Application of Signal Detection in the Taiwan National Adverse Drug Reaction Reporting System: Metformin-Associated Lactic Acidosis (MALA) as an Example
P. Chao, W. Ke, W. Chen and A. On
PP017. Safety Profile of Antiviral Analogues: A Case/Non-Case Study Using the Italian Spontaneous Reporting Database
R. Bonaiuti, A. Pugi, M. Tuccori , M. Moschini,1 V. Maggini, L. Sottosanti, S. Potenza, F. Ferrazin, A. Mugelli, A. Vannacci and F. Lapi
PP018. Performance of Disproportionality Analysis when Applying Information of Concomitant Medication and Labelling
E. van Puijenbroek, J. Scholl and K. van Grootheest
PP019. Trending and Signalling of Medical Device Safety Reports
F. Schneiweiss, D. Villegas, W. Ye, O. Ayela Uwangue, J. Babuschak and S. Yonren
PP020. Three-Year Experience with Safety Signal Detection Process Tracking at Sanofi Pasteur
C. David, C. Legendre, G. Ferreira and A. Khromava
PP021. An Assessment of Bayesian Confidence Propagation Neural Network Method for Adverse Drug Reaction Signal Generation in Presence of Reporting Bias
P. Ghosh and A. Dewanji
PP022. When Databases Collide: The Impact on Data Mining Analysis of Merging Two Large Pharmaceutical Company Safety Data Bases
M. Hauben and E. Hung
PP023. Comparison of Safety Profile of Racemate Drugs and Their Enantiomers: Analysis of the French Pharmacovigilance Database
C. Caillet, L. Moachon, J. Montastruc and H. Bagheri
PP024. Oseltamivir and Pancreatitis
M. Kriska, R. Hudec, L. Sallstedt and R. Hill
PP025. Drug-Induced Hyponatremia: A Quantitative Exploration of Suspect Drugs and Drug Interactions in the WHO UMC Database
M. Hauben and R. Mozenter
PP026. Analysis of the French Pharmacovigilance Database for a Controversial Adverse Drug Reactions: Bleeding Risk in Patients Exposed to Antiplatelet Plus Serotonin Reuptake Inhibitor (SRIs) Drugs
F. Maschino, C. Hurault Delarue, L. Chebbane, V. Fabry, J. Montastruc and H. Bagheri
PP027. Imatinib and Hyperparathyroidism
M. Teeling, S. Ghareh Chaie and J. Johansson
PP028. Non-Steroidal Anti-Inflammatory Drugs-Associated Acute Generalized Exanthematous Pustulosis (AGEP): Reports from the Italian Pharmacovigilance Database
M. Donati, L. Sottosanti , S. Potenza, L. Catalano, F.Ferrazin, S. Opri, R. Leone and A. Conforti
PP029. Automated Signal Detection Methods May not be Applicable to Small and Medium-Sized Drug Safety Databases
Y. Moride, F. Thiessard and B. Be´gaud
PP030. Signal Detection: Thailand Experiences
C. Jamekornkul and W. Suwankesawong
PP031. Electronic Healthcare Record (EHR) Databases for Drug Safety Signal Detection: What CanWe Expect?
P.M. Coloma, G. Trifiro`,M.J. Schuemie,R. Gini, R. Herings, J. Hippisley Cox, G. Mazzaglia,G. Picelli, G. Corrao, L. Pedersen, J. Van Der Lei and M. Sturkenboom
PP032. ARITMO Project. Ventricular Arrhythmia Associated to Antimicrobials, Antipsychotics and H1-Antihistamines: an Analysis of the French Spontaneous Reporting Database
F. Salvo, A. Fourrier Reglat, U. Moretti , P. Auriche, N. Moore, M.C. Sturkenboom, F. De Ponti and A. Pariente
PP033. ARITMO Project. Competition Bias for Ventricular Arrhythmia between AZERT Drugs and Antipsychotics: An Analysis of the French Spontaneous Reporting Database
A. Fourrier Reglat, F. Salvo, U. Moretti , P. Auriche, N. Moore, M. Sturkenboom, F. De Ponti and A. Pariente
PP034. Signal Detection Based on Proportional Reporting Ratio in Spontaneous Reporting Databases: Comparison of the Evans Criteria versus False Discovery Rate
M. Rottenkolber, S. Schmiedl, S. Mueller, K. Salje, M. Hippius, A. Scheuerlein, K. Farker, P.A. Thu¨rmann and J. Hasford
PP035. Event Competition Bias in Signal Detection from Spontaneous Reporting:
Could what we Know Hide what we Ignore?
A. Pariente, F. Salvo, F. Leborgne, F. Thiessard, F. Bazin, N. Moore and B. Be´gaud
PP036. A Brief View: PSUR and National Report Assessment Department Operations Procedure in Turkey
O. Karakoyunlu, S. Altınel, E. Topcu, E. Sen, S. Polat, H. Ilbars, H. Ozbek and S. Kerman
PP037. Classification of PSUR and National Reports, which Were Assessed in 2010 According to ATC Classification
O. Karakoyunlu, S. Altınel, E. Topcu, E.Sen, S. Polat, H. Ilbars, H. Ozbek and S. Kerman
PP038. Palonosetron Surveillance Data: A Favourable Benefit-Risk Balance in Post-Marketing Use
M. Bertazzoli, F. Tescione, S. Sebastianiand S. Cantoreggi
PP039. Risk of Autoimmune Disorders after Immunisation with Influenza A/H1N1 Vaccines with and without Adjuvant: Preliminary Results from EudraVigilance
A. Isai, S. Le Meur, A. Hidalgo Simon, P. Arlett and X. Kurz
PP040. Vaccine Pharmacovigilance: Routine Use in Children
S.E. Aghahowa
PP041. Serbian National Pharmacovigilance Centre Review of AEFI During Intensive Monitoring of Focetria Vaccine Administration
J. Pilic, J. Babic and M. Eric
PP042. Risk of Febrile Seizures Associated with the Measles-Mumps-Rubella-Varicella Combination Vaccine (MMRV): Data from Spontaneous Reporting in Italy
U. Moretti, G. Zanoni , A. Conforti,R. Lora, E. Arzenton, F. Trotta and C. Santuccio
PP043. Spontaneous Reporting of Adverse Reactions to Pneumococcal Vaccination in Children
C. Santuccio, F. Menniti Ippolito, L. Tartaglia, F. Trotta, D. Morlino and U. Moretti
PP044. 2009 H1N1 Influenza Vaccines in Pregnant Women: A Survey in South West France
E. Omon, C. Damase Michel, C. Hurault, I. Lacroix, J. Montastruc, S. Oustric and B. Escourrou
PP045. Monitoring Adverse Reactions of the Cantgrip_Vaccine
C. Pop, A.M. Farcas, D.C. Leucuta, C. Bucsa, D. Faraian, D.R. Florea,D. Tatulescu and M.T. Bojita
PP046. Abscess at Injection Site with Diphtheria,Tetanus, Pertussis and Haemophilus Influenzae Type b Vaccine (Analysis of Moroccan Pharmacovigilance Database)
A. Tebaa, A. Zineddine and R. Soulaymani Bencheikh
PP047. Impact of Non-Vaccine-Related Reports on Statistical Signal Detection for Vaccines in Spontaneous Reporting Databases
U. Moretti, R. Lora, G. Zanoni , L. Tartaglia, F. Ferrazin, G.P. Velo and C. Santuccio
PP048. Review of Adverse Events Following Immunization Submitted to WHO-UMC by Turkish Pharmacovigilance Center (TUFAM) between 2005 and May 2011
D. Aydinkarahaliloglu, Y. Kasap, E. Aykac¸,G. Sagis, C. Babacanoglu, H. Ilbars,A. Kara, H.Ozbek and S. Kerman
PP049. Adverse Events Following Immunization with OPV in Adults in Kinshasa: Preliminary Results
D.B. Nzolo, D.B. Pandi, T.N. Mpiempie, S.B. Banzundama, B.L. Mvete, O. Mboma, M.M. Lusakibanza, Y.N. Lula, F.B. Makila, G.K. Mesia, C.N. Nsibu and G.L. Tona
PP050. Surveillance of Adverse Events Following Immunization (AEFI) with Trivalent Inactivated Influenza Vaccine in Canada: Was an Increase in the Number of Febrile Seizures Observed for the 2010–2011 Vaccination Campaign?
J. Lafleche, R. Pless and B. Law
PP051. Antimalarial Drugs Pharmacovigilance in National Malaria Control Programme of DR Congo
Y.N. Lula, J.Y. Liwono, P.N. Ntamabyaliro, D.B. Nzolo, B.Y. Salumu, B.L. Mvete, G.K. Mesia,S.M. Mampunza and G.L. Tona
PP052. Adverse Drug Reactions to Antiretroviral Drugs at Lagos University Teaching Hospital HIV Clinic, Lagos, South West Nigeria
I.A. Oreagba, O. Agede, T. Adeyemo, C.S. Ejekam, O. Opanuga, S. Akanmu, O. Awodele, T. Adeyemo and S. Akanmu
PP053. Spontaneous Adverse Event Reporting of First-Line Anti-Tuberculosis Drugs in One Regional Pharmacovigilance Center
H. Park, G. Jung, H. Hwang, K. Shin, M. Kim, G. Lee, K. Kim,
M. Lee and S. Park
PP054. Safety of Artesunate Amodiaquine (AS/AQ) and Artemether- Lumefantrine (AL) in Accra, Ghana: A Cohort Study
A.N. Dodoo, A. Adomako Bonsu, M. Abdul Sulley and C. Otieku Boadu
PP055. Antiretrovirals and Pregnancy: A Case Series
E. Sole´, G. Maura, E. Herlem, M. Germain and T. Trenque
PP056. Strengthening Pharmacovigilance System Through Leveraging Resources from Public Health Programmes in Nigeria
A.I. Osakwe, U.G. Elemuwa, B.O. Akinola and C.K. Suku
PP057. Establishing a Pharmacovigilance Database in Romania: Practical Value
A.M. Farcas, T. Chiorean, D. Leucuta, R. Cherechesand M. Bojita
PP058. Knowledge of Healthcare Professionals to Report Adverse Drug Reaction in Nepal: A Preliminary Study
S. Kc, P. Tragulpiankit, S. Gorsanan and R. Edwards
PP059. Provision and Accuracy of Safety Information on Package Inserts of Selected Registered Medicines in Sudan
S. Osman, Z. Mutasim, A. Suliman and Y. Hamid
PP060. A Difference in ADR (Adverse Drug Reaction) Mortality Rate in Thai Tuberculosis Patients between Year 2008–2009
S. Wechwithan and P. Sriphiromya
PP061. Analysis of Characteristics about Drug Adverse Events Reports Received in KFDA during 2008–2010
J. Ha, Y. Kim and M. Chung
PP062. Tamoxifen-Duloxetine: Risk of Reduced Therapeutic Response of Tamoxifen
J. Mahe, G. Veyrac, J. Mathevet and P. Jolliet
PP063. Interaction between Levothyroxine and Ritonavir-Boosted Amprenavir in Human Immunodeficiency Virus Infected Patients
A. Ruellan, G. Veyrac, M. Lefebvre, B. Bonnet, C. Brunet Francois and P. Jolliet
PP064. Implementing Effective PV in National Malaria Control Programme of DR Congo
Y.N. Lula, P.N. Ntamabyaliro, J.Y. Liwono, T.N. Mpiempie, S.B. Bazundama, G.K. Mesia, C.N. Nsibu and G.L. Tona
PP065. A Suspected Local Eruption due to Simethicone
G. Lakhoua, S. El Aidli, R. Daghfous and M. Lakhal
PP066. Peginterferon Alpha 2a Side Effects: A Retrospective Study
G. Lakhoua, S. El Aidli, A. Zaiem, S. Kastalli, I. Aouinti, R. Daghfous and M. Lakhal
PP067. Use of Intensive Pharmacovigilance by Specialist Physicians:
Prescription of Thalidomide in Venezuela 2009–2010
L.H. Valdivieso and B.C. Ruiz
PP068. Cost-Benefit Analysis of Pharmacist Interventions Related to Determine Preventable Adverse Drug Reactions for Hospitalized Patients in Thailand
T. Uaviseswong, U. Chaikledkaew and P. Tragulpiankit
PP069. From Quality to Safety by Using Quality by Design (qbd)
B. Aksu, A. Paradkar, M. De Matas, O .Ozer, T. Guneri and P. York
PP070. Impact of Polypharmacy on Adverse Drug Reactions Among Geriatric Patients in Penang Hospital
Y.W. Kassab, M.F. Najjar, H.A. Abdulrazzaq, Y. Hassan, N. Abd Aziz and R. Ghazali
PP071. Improving Yellow Card to Detect Medication Errors
L. Alj, R. Benkirane, S. Pal, S. Olsson and R. Soulaymani
PP072. The Role of Pharmacovigilance Centres in Medication Errors Management
L. Alj, R. Benkirane and R. Soulaymani
PP073. Medication Errors in an Hospital Ward
C. Le Beller, M. Soyer, F. Bellenfant, A. Lillo Le Louet and D. Journois
PP074. Safety of Atrovent_ CFC-Free MDI (Metered Dose Inhaler): An Example of Protopathic Bias in Observational Cohort Studies
V. Osborne, D. Layton, E. Tong and S. Shakir
PP075. Active Surveillance of the Introduction of Atrovent_ CFC-free MDI (Metered Dose Inhaler) into General Practice in England: Characteristics of Users
V. Osborne, D. Layton, E. Tong and S. Shakir
PP076. Analysis of Vildagliptin Utilisation from Interim Prescription-Event Monitoring (PEM) Results: Focus on ‘Off Label’ use in Support of Risk Management
V. Osborne, D. Layton, C. Fogg and S. Shakir
PP077. Drug Utilisation Data for Seroquel XL: Results of a First Interim Modified PEM Study Report
A. Gilchrist, M. Davies, D. Layton and S. Shakir
PP078. FDA Final Rule on IND Safety Reporting: Impact to Your Clinical Studies
S. Van Doren
PP079. Reliability of the Reported Ingested Dose of Acetaminophen for Predicting the Risk of Toxicity in Acetaminophen Overdose Patients
S.H. Zyoud, R. Awang, S. Syed Sulaiman and S.W. Al Jabi
PP080. Adverse Drug Events in Hospitalized Patients with Acetaminophen Overdose Treated with Intravenous N-Acetylcysteine
S.H. Zyoud, R. Awang, S. Syed Sulaiman and S.W. Al Jabi
PP081. ‘‘Serious’’ Cutaneous Reactions with ProteinKinase Inhibitors
E. Bondon Guitton, E. Faye, P. Olivier Abbal, H. Bagheri, J. Montastruc
PP082. Pharmacovigilance in Kyrgyzstan
S. Moldoisaeva and A. Zurdinov
PP083. Pharmacovigilance Committee Activities of the Association of Research-Based Pharmaceutical Companies after the Release of Pharmacovigilance Regulation in Turkey
A. Erkahraman, Z. Nefesoglu and S. Epceli
PP084. Selective Serotonin Reuptake Inhibitors and Gastrointestinal Bleeding: A Meta-Analysis
A. Carvajal, C. Trecen˜o, M. Sa´inz, I. Salado, N. Jimeno, V. Velasco and L. Martı´n Arias
PP085. Therapeutic Drug Monitoring and Pharmacogenetic Tests: New Tools to Prevent Drug Side Effects
E. My Elhassan, F. Houda, E. Afaf and H. Farid
PP086. Benign Intracranial Hypertension Associated to Progesterone Utrogestan:
About One Case
A. Elrherbi, M.E. Elkarimi, H. Filali, A. Tazi and F. Hakkou
PP087. A Recurrent Drug Rash with Eosinophilia and Systemic Symptoms
N. Fathallah, C. Jeddi , R. Slim,C. Belajouza,R. Nouira, C. Ben Salem and K. Bouraoui
PP088. Codeine-Induced Generalized Dermatitis
N. Fathallah, B. Trimech, L. Boussofara, I. Ghali, R. Slim, C. Ben Salem and K. Bouraoui
PP089. Paradoxal Exacerbation of Rash Under Budesonide Therapy
N. Fathallah, S. Chatti , R. Slim, C. Belajouza, C. Ben Salem and K. Bouraoui
PP090. Rituximab-Induced Leucocytoclastic Vasculitis: A Case Report with Brief Review of Literature
N. Fathallah, A. Alaoua, R. Slim, F.Bahri , C. Ben Salem and K. Bouraoui
PP091. Reactivation of Pulmonary and Cutaneous Sarcoidosis after Treatment for Chronic Hepatitis C with Pegylated Interferon Alpha and Ribavirin
N. Fathallah, M. Zamy, R. Slim, K. Bouraoui, C. Ben Salem and M. Biour
PP092. Esomeprazole-Induced Recurrent Anaphylactic Shock with Positive Skin Prick Tests
N. Fathallah,A. Alaoua, R. Slim, F. Bahri , K. Bouraoui and C. Ben Salem
PP093. A Study on Assessment, Monitoring and Reporting of Adverse Drug Reactions in an Indian Hospital
S. Palanisamy, K.S. Arul Kumaran and A. Rajasekaran
PP094. Does the Logistic Method Perform Better than the Naranjo Algorithm for Causality Assessment of Adverse Drug Reactions?
H. The´ophile, M. Andre´, Y. Arimone, F. Haramburu,
G. Miremont Salame´ and B. Be´gaud
PP095. Montelukast and Suicide: Causality Assessment Using Spontaneous Reports and Bradford Hill Guidelines
N. Iessa, K. Star, L. Wilton, S. Curran, R. Edwards, J.K. Aronson, M. Murray, F.M. Besag and I.C. Wong
PP096. Causality Assessment of Adverse Drug Reaction: Comparison between Pharmaceutical Industry and Pharmacovigilance Centre Using the Updated French Causality Assessment Method
M.B. Valnet Rabier, Y. Arimone, I. Bidault, J.P. Dutertre, M. Ge´rardin, C. Guy, F. Haramburu, D. Hillaire Buys, C. Meglio, C. Penfornis and H. The´ophile
PP097. Role of Drugs in Acute Liver Failure Leading to Transplantation: Results from the 7-Country Study of Acute Liver Transplant (SALT)
E. Gulmez, S. Lignot, D. Larrey, G. Pageaux, Y. Horsmans, B. Stricker, J. Bernuau, F. Bissoli, D. Thorburn, J. Montastruc, F. Hamoud,S. Micon, P. Blin and N. Moore
PP098. Alendronate Tolerability before and after Market Introduction of Generics
J. Petersen, T. Jan, K. Donegan and S. Seabroke
PP099. Investigation of Second Primary Malignancies (SPM) in Multiple Myeloma (MM) Patients Treated with Lenalidomide
N. Minton, C. Castaneda, L. Weiss, N. Brandenburg, D. Gary, J. Freeman, R. Delap, R. Knight, A. Glasmacher, K. Rupalla, J. Zhang and Z. Yu
PP100. Completeness of Initial Serious Adverse Event Forms from Clinical Trial Safety Reporting: A Prospective Chart Survey
P. Ghadge, S. Valsan and P. Watson
PP101. Reasons for the Discontinuation of Treatment with Infliximab at Angers University Hospital: A Follow-Up of 5 Years
H. Martin Huyghe, D. Bourneau Martin, A. Marie, B. Bouvard, E. Metivier, F. Moal, Y. Le Corre, A. Jamet, L. Lagarce and P. Laine´ Cessac
PP102. A Recurrent Acute Urinary Retention in a Child Following a Medication Error
D. Soussi Tanani, A. Chebat, R. Benkirane and R. Soulaymani Bencheikh
PP103. Therapeutic Errors in Older Adults
H. Filali, I. Rahmoun, H. Elkaromi, D. M’zah, A. Miftah and F. Hakkou
PP104. A Pilot Prospective Observational Hospital Study on Adverse Drug Reactions due to Medication Errors
R. Leone,L. Magro, P. D’incau, P. Minuz, F. Paluani, R. Nuvolari , S. Bonafini and G.P. Velo
PP105. Preventability Analysis of Adverse Drug Reactions Detected by Stimulated Spontaneous Reporting in Two Internal Medicine Departments in Romania
A.M. Farcas, C. Bucsa, A. Sinpetrean, C. Mogosan, D. Dumitrascu, A. Achimas and M. Bojita
PP106. Omitted Doses in a Paediatric Intensive Care Unit: A Pilot Study
A.R. Cox, F. Walele and R. Isaac
PP107. Leg Amputation Following Intramuscular Injection of Iron Dextran in a 32-Year-Old Woman: a Medication Error
G. Shalviri, K. Gholami and N. Javidnikou
PP108. Medication Error in the Administration of Caffeine in Newborn: Case Report
R. Sahnoun, E. Gaı¨es, N. Jebabli, S. Trabelsi, I. Salouage, R. Charfi, M. Lakhal and A. Klouz
PP109. Are Newly-Introduced Drugs Used Appropriately? An Audit of Rivaroxaban
C. Higham and C. Anton
PP110. National Observational Study on Rational Drug Prescribing and Dispensing in Pharmacies (Morocco)
A. Khattabi, R. Benkirane and R. Soulaymani
PP111. Actions Taken For Laroxyl (Amitriptyline) Intoxication in Children
D. Aydinkarahaliloglu, E. Aykac¸, Y. Kasap, G. Sagis ,C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP112. Medication Error with High-Dose MTX Treatment
I. Salouage, E. Gaies, S. Trabelsi, R. Charfi, N. Jebabli, M. Lakhal and A. Klouz
PP113. Preventability of Adverse Drug Reactions (ADRs) Leading to Hospital Admissions
L. Alesso, R. Herrera Comoglio and C. Nota
PP114. Effectiveness of Proactive-Approach in a Pharmacovigilance Unit:
Review and Analysis of 3003 Notifications Received
G.A. Keller, M.L. Ponte, P.A. Alvarez, A. Campos and G. Di Girolamo
PP115. Pharmacovigilance on Hospital Admission: Medication Lists and Beyond
P.A. Alvarez, V. Castro, F. Santini, C. Soler, R. Gutierrez, F. Bril, G.A. Keller, G. Di Girolamo and C. Lopez Saubidet
PP116. Adverse Drug Events as a Reason for Admission in a University Teaching Hospital in Argentina
P.A. Alvarez, V. Castro, F. Santini, C. Soler, R. Gutierrez,
F. Bril, G.A. Keller, G. Di Girolamo and C. Lopez Saubidet
PP117. Evaluation of QT-Interval Prolongation: Detection of most Frequently Associated Drugs in Clinical Oncology
C. Bagnes, G.A. Keller, P.A. Alvarez, M.L. Ponte, W. Belloso, A. Campos and G. Di Girolamo
PP118. Evaluation of QT-Interval Prolongation: A Multicenter Study to Detect Drugs more Frequently Associated in the Clinical Practice
G.A. Keller, P.A. Alvarez, M.L. Ponte, W. Belloso, C. Bagnes, A. Campos and G. Di Girolamo
PP119. Suicide Attempts in Mali
H. Hami, T. Diallo, A. Maı¨ga, A. Mokhtari and A. Soulaymani
PP120. High Dimensional versus Conventional Propensity Score Matching to Reduce Confounding in a Study of Coxibs versus Non
E. Garbe, S. Kloss, W. Schill, M. Suling and S. Schneeweiss
PP121. Risk of Subarachnoid Hemorrhage Associated with Outpatient Anticoagulant Use
S. Behr and E. Garbe
PP122. Persistence of Pharmacological Treatment into Adulthood for ADHD Patients who Started Treatment in Childhood or Adolescence in UK Primary Care
S. Mccarthy, L. Wilton,M. Murray,P. Hodgkins, P. Asherson and I.C. Wong
PP123. The Epidemiology of Pharmacologically-Treated Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults in UK Primary Care
S. McCarthy, L. Wilton, M. Murray, P. Hodgkins, P. Asherson and I.C. Wong
PP124. Development of Search Strategies to Identify Reports of Off-Label Drug Use in EMBASE
B. Mesgarpour, M. Muller and H. Herkner
PP125. Detecting Adverse Drug Event by Trigger Tool at a Province Hospital, Thailand
P. Tragulpiankit, N. Yeesoonpan,W. Keratitechakorn, T. Ninsananda, T. Uaviseswong, U. Chaikledkaew, B. Chindavijak, S. Chulavatnatol and AdcoptWorking Team
PP126. Is Chest Pain Related to Ischemic Heart Diseases Only in Cardiac Patients?
H.A. Abdulrazzaq, S. Syed Sulaiman, Y.W. Kassab and O. Ismail
PP127. Skin Rash Induced by Statin in Cardiac Outpatients of Penang General Hospital, Malaysia
H.A. Abdulrazzaq, S. Syed Sulaiman,Y.W. Kassab and O. Ismail
PP128. Stevens - Johnson syndrome and Drugs and Vaccines: A Case-Control Study in Children
F. Menniti Ippolito, R. Rossi , G. Traversa, R. Da Cas,C. Rafaniello, N. Mores, G. Bersani, N.Pirozzi ,U. Raucci and Italian Multicenter Study Group on Safety of Drugs and Vaccines in Children
PP129. Intensive Monitoring Programme of Adverse Drug Reactions in Emergency Department
(MEREAFaPS Study): The Tuscan Experience
M. Tuccori, A. Pergola, M. Rossi,A. Capogrosso, M. Moschini,4 A. Vannacci,4 F. Rimoli,5 E. Cecchi,6 E. Ruggiero,S. Mantarro, L. Picchianti, M.C. Leo, G. Giustarini, A. Testi, S. Montagnani , C. Scollo, M. Santini, L. Spisni, F. Mannelli, M.S. Verzuri,T. Corona and C. Blandizzi
PP130. EFEMERIS (Evaluation chez la Femme Enceinte des MEdicaments et de leurs RISques), the French Prescription Database in Pregnant Women: A 4 Year-Follow Up
I. Lacroix, C. Hurault Delarue, S. Kessler, C. Guitard, A. Berrebi , S. Vidal, C. Albouy Cossard,
R. Bourrel, E. Elefant,7 J. Montastruc, H. Bagheri and C. Damase Michel
PP131. Poor Social Environment and Altered Nutritional Status are Associated with Adverse Drug Reactions: A Hospital-Based Case-Control Study
S. Dabadie, P. Noize, M. Vandenhende, G. Miremont,Salame, N. Moore, P. Morlat, J. Pometan and F. Bonnet
PP132. Long-Term Increased Risk of Dementia in Elderly Benzodiazepine Users:
Results from a Cohort Study
S. Billioti De Gage, B. Be´gaud, H. Verdoux,J. Dartigues,K. Pere`s, F. Bazin and A. Pariente
PP133. Enhancing the Presentation and Evaluation of Cumulative Post-Marketing Safety Data: A Pilot Study
A. Gilchrist, D. Layton, C. Fogg and S. Shakir
PP134. Analysis of Utilisation of Ibandronic Acid from Prescription-Event Monitoring (PEM): Focus on ‘Off Label’ Use in Support of Risk Management
A. Gilchrist, V. Osborne, D. Layton and S. Shakir
PP135. Worldwide Survey on Post-Authorization Safety Studies: Review of International, Regional and National Guidelines
L. Montigon, G. Ferreira, C. David and A. Khromava
PP136. Potential Determinants of Suicidal Ideation and Suicide Attempt in users of Duloxetine
M. Al Shukri
PP137. Hepatotoxicity Associated with Agomelatine: A Case/Non-Case Study
M. Saiz, T. Falomir, C. Treceno, I. Salado, N. Jimeno, L. Martın Arias, V. Velasco and A. Carvajal
PP138. The Safety of Amlodipine and Valsartan Single Pill Combination in Hypertensive Patients
P. Kizilirmak, M. Berktas and B. Boyaci
PP139. Effect of Long-Term Use of Proton Pump Inhibitor on Atrophic Gastritis and Gastric Cancer: A 5-Year Longitudinal Cohort Study in South Korea
K. Hong,S. Kim, S. Kang and J. Kim
PP140. Efficacy and Safety of Valsartan and Amlodipine Single Pill Combination in Hypertensive Patients: The Compliance Results
P. Kizilirmak, M. Berktas and B. Boyaci
PP141. Reported Case of Tissue Necrosis in Patient Who Received Intramuscular
Diclofenac Injection
M.M. Younus, J.M. Kurmanji and M.F. Abdulqader
PP142. Rapid Bilateral Deafness Onset Associated with Concomitant Administration of Gentamicin and Kanamycin in an Adult: Case Report
B.Y. Salumu, P.N. Ntamabyaliro, Y.N. Lula, G.K. Mesia and G.L. Tona
PP143. Adverse Drug Reactions in Relation with ‘Off-Label’ Use of Aloe Vera Pulp
S. Skalli, R. Benkirane and R. Soulaymani Bencheikh
PP144. Use of Off-Label and Unlicensed Drugs in Paediatrics: Review
J.J. Joaquim, C.I. Fonseca, C.F. Roma˜o and T.S. Pires
PP145. Misuse of Proparacaine Hydrochloride
D.N. Aydinkarahaliloglu,V. Dayanır,2 G. Sagis, Y. Kasap, E. Aykac¸, C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP146. Knowledge and Attitude of Doctors to Adverse Drug Reactions Reporting and Need of Pharmacovigilance Training in Kolhapur, Maharashtra, India
M.A. Burande, A.R. Burande, S. Sahni and S. Lohan
PP147. Evaluation of General Practitioners and Community Pharmacists’ Perception Towards Consumer Reporting of Adverse Drug Reactions (ADRs) in Penang Island
M.A. Alshakka, M.M. Ibrahim and M.A. Hassali
PP148. Evaluation of General Public Perception Towards Adverse Drug Reaction Reporting
M.A. Alshakka, M.M. Ibrahim and M.A. Hassali
PP149. Risk of Suicidality Events in Patients Taking Atomoxetine:
Results of a Matched Cohort Analysis
M. Davies, D. Layton, E. Tong and S. Shakir
PP150. Experiences and Preferences of Healthcare Professionals with Regard to Direct Healthcare Professional Communications
S. Piening, F.M. Haaijer Ruskamp, P.A. De Graeff, S.M. Straus and P.G. Mol
PP151. Implanon and Reports of Unintended Pregnancy: Media Interest in UK
D. Mahoney, J. Woolley and M. Jadeja
PP152. Evaluating the Effectiveness of Health Product Risk Communications:
Health Canada’s Strategic Approach
D. Jurgens, V. Hogan, G. Condran, L. Adewoye and S. Reid
PP153. An Investigation on the Perception of the Risk on the Use of Medicinal Plants Commonly Used and Sold by Herbalists in Tuscany
E. Gallo, E. Lucenteforte, S. Harrison, M. Di Pirro, M. Moschini, L. Gori, V. Mascherini, F. Firenzuoli, A. Mugelli and A. Vannacci
PP154. Pharmaceutical Sales Representatives and Patient Safety: A Comparative Cross-Sectional Survey of Information Quality in Canada, France and the U.S
B. Mintzes, M. Beaulieu, M. Wilkes and J. Montastruc
PP155. Identification of Adverse Drug Reactions Associated with Counterfeit Anti-Diabetic Herbal Products
F.A. Al Braik, A.S. Elgharbawy and M.Y. Hasan
PP156. Hypoglycaemic Episodes Leading to Hospitalisation in Departments of Internal Medicine
P. Thurmann, S. Schmiedl,M. Rottenkolber, J. Szymanski, B. Drewelow, S. Muller, A. Zachow, W. Siegmund, K. Salje, M. Arnold, M. Hippius, A. Scheuerlein, K. Farker and J.Hasford
PP157. The Diabetic Phytovigilance what does in Morocco?
Y. Khabbal, F. Ajdi , Y. Cherrah, K. Amazian and N. Chami
PP158. Gender Differences in Adverse Drug Reaction (ADR) Reporting in Children in Norway 2001–2010
J. Bergman and J. Schjøtt
PP159. Drug Treatment of ADHD in Children and Youths in Germany
E. Garbe, R.T. Mikolajczyk, A.A. Kraut and I. Langner
PP160. Safe Method of Propofol Infusion in Children: Pharmacokinetics and Pharmacodynamics of Lipid Emulsion Propofol in Children
H. Byon, J. Kim, H. Kim and C. Kim
PP161. Risk of Cardiac Events in Patients Taking Atomoxetine: Results of a Matched Cohort Analysis
M. Davies, D. Layton, E. Tong and S. Shakir
PP162. Acute Renal Failure in an Infant Following Ingestion of Peganum Harmala
D. Soussi Tanani, N. Badrane, A. Chebat, R. Benkirane and R. Soulaymani Bencheik
PP163. Individual Case Safety Reports and Useful Clinical Information
K. Star, N.B. Almandil, I.C. Wong and I. Edwards
PP164. Using PMSI Database to Identify Adverse Drug Reactions in a Pediatric University Hospital
A. Batz, E. Bondon Guitton, G. Durrieu, M. Lapeyre Mestre, D. Petiot and J. Montastruc
PP165. Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study in Children in Sikasso (Mali)
A. Oumar, K. Diallo, L. Samake, I. Sidibe, B. Togo, M. Sylla and S. Dao
PP166. Drug-Related Problems in Hospitalised Children in the United Kingdom and Saudi Arabia
A.N. Rashed, A. Neubert, S. Tomlin, J. Jackman, H. Alhamdan, A. Shaikh, A. Attar, M. Aseeri4 and I.C. Wong
PP167. Drug Use and Acute Liver Injury in Children: Signal Detection Using Multiple Healthcare Databases
C. Ferrajolo, G. Trifiro, P.M. Coloma, M.J. Schuemie, R. Gini, R. Herings,J. Hippisley Cox, G. Mazzaglia, G. Picelli,L.Scotti, L. Pedersen, J. Van Der Lei and M. Sturkenboom
PP168. Meta-Analysis of Malignancy Risk in Rheumatoid Arthritis from 29 Trials:
Comparison of Intention to Treat and Per Protocol Analyses
G. Moulis, A. Sommet, F. Montastruc, J. Be´ne´, L. Sailler, J. Montastruc and M. Lapeyre Mestre
PP169. Intensive Monitoring of Adverse Drug Reactions in Patients Receiving Pharmacological Treatments for Rheumatoid Arthritis and Other Rheumatologic Diseases, with Particular Focus on Biotechnological Drugs: The ASTRAGALUS Study
M. Tuccori, G. Giustarini , L. Bazzichi, S. Manganelli, F.Peruzzi, O.M. Sacu, L. Picchianti , A. Capogrosso,M. Rossi ,F. Sernissi, C. Giacomelli, R. Neri, M.G. De Montis, F. Nacci, F. Lapi, C. Scollo, S. Mantarro, S. Montagnani , L. Sabadini,A. Testi, E. Ruggiero, A. Vannacci, A.Mugelli, S. Bombardieri, M. Matucci Cerinic, M. Galeazzi and C. Blandizzi
PP170. Tumor Necrosis Factor Inhibitors and Cancer: A 10-Year Review of the French Pharmacovigilance Database
L. Saliba, N. Petitpain, B. Baldin, P. Gillet, J. Montastruc and H. Bagheri
PP171. Anaphylactic Reactions to Biological Drugs: Data from Spontaneous Reporting in Italy
U. Moretti, M. Donati, L. Sottosanti , L.Catalano, E. Boccola and G. Zanoni
PP172. Presentation of Drug Safety Surveillance Form and Tuberculosis and Malignancy Risk in Patients Using Anti-TNF Drugs
D. Aydinkarahaliloglu,Y. Kasap, E. Aykac¸, G. Sagis¸ C. Babacanoglu, H. Ilbars, M. Turgay, H. Ozbek andS. Kerman
PP173. Risk of Activation or Reactivation of Latent Tuberculosis (TB) Associated with Monoclonal Antibody Therapy
W. Huang, S. Samalulu and D. Vu
PP174. Herceptin_ (Trastusumab) and the Incidence of Spontaneous Abortion
S. Daniels,M. Johnston and L. Hiles
PP175. Impact of Adverse Drug Reactions of Drug-Substrates of the Metabolic Enzyme Cytochrome P450 2C9 and/or the Transporter Protein Pgp in a National Database
V. Macolic Sarinic, N. Bozina, N. Mirosevic Skvrce, D. Krnic, M. Banovac, S. Arapovic, A. Andric and S. Tomic
PP176. Determination of Estrogens in Inputs and Outputs of WWTPs Using HPLC with UV Detection
A.P. Fonseca, S.M. Cardoso and V.I. Esteves
PP177. Acute and Chronic Effects of Diclofenac in D. magna and D. longispina
J.J. Joaquim, C. Ribeiro, J. Pereira and F.J. Goncalves
PP178. Approaching a New Method to Express the Incidence of Adverse Drug Reactions in Hospitalized Patients
M.L. Ponte, H.A. Serra and A. Wachs
PP179. Nephrotoxicity Induced by Herbal Medicines Used in DR Congo
C.V. Zinga, N.M. Nseka, G.K. Mesia, E.K. Sumaili , F.B. Lepira, P.N. Ntamabyaliro, Y.N. Lula and G.L. Tona
PP180. Online Notifications of Adverse Drug Reactions: A Study in Midi-Pyre´ne´es Pharmacovigilance Regional Centre
D. Abadie, M. Bert, G. Durrieu and J. Montastruc
PP181. Comparison of Signal Detection Using Healthcare Database Network versus Spontaneous Reporting System Database: the EU-ADR Experience
G. Trifiro, V. Patadia, P.M. Coloma, M.J. Schuemie,R. Gini, R. Herings, J. Hippisley Cox, G. Mazzaglia, G. Picelli,
L. Scotti, L. Pedersen,P. Avillach, J. van der Lei and M. Sturkenboom
PP182. Drug Safety Officers and Yellow Boxes: New Developments in Reporting Adverse Drug Reactions and Medication Errors in Hospitals
G. Shalviri,K. Gholami and M. Fazlollahi
PP183. Harmonization in Periodic Safety Reporting for Investigational Products: Differences between Current Annual Safety Report and New Development Safety Update Report
H. Tønsberg, S. Blomvik, L. Storm and S. Lindequist
PP184. Drug-Drug Interactions: The Detection and Negative Clinical Consequences in Hospitalized Patients
C.D. Bucsa, A.M. Farcas, I. Cazacu and M.T. Bojita
PP185. Acute Hepatitis Associated with Use of Green Tea and Oral Contraceptives: A Case Report
E. Gallo, A. Pugi, V. Maggini,G. Pieraccini, R. Notaro,V. Annese, A. Mugelli, F. Firenzuoli and A. Vannacci
PP186. Herbal Hepatotoxicity: Data from the WHO-UMC Database
K. Ilic,M. Petronijevic, A. Suzuki and M. Blagojevic
PP187. Physicochemical Incompatibility of Injectable Drugs (Assessment of Knowledge Care Professionals)
Y. Khabbal, M. Ait El Cadi and Y. Cherrah
PP188. Early Interaction between Tacrolimus and Rifampin
R. Charfi, I. Salouage, R. Sahnoun, S. Trabelsi, E. Gaies, N. Jebabli, M. Lakhal and A. Klouz
PP189. Acute Renal Failure, Consequence of Perindopril and Ketoprofen Therapy: A Case Report
C.D. Bucs¸ a, I. Cazacu, A.M. Farcas¸ , A. Achimas¸ and M. Bojita
PP190. Interaction between Tacrolimus and Azole Antifugals Drugs
N. Jebabli, I. Salouage, E. Gaı¨es, S. Trabelsi, R. Charfi, R. Sahnoun, M. Lakhal and A. Klouz
PP191. ADRs in Elderly Hospitalized Patients
M.L. Ponte, G. Keller, G. Di Girolamo and W. Adolfo
PP192. Quinolone-Induced Glucose Homeostasis Impairment
M.L. Ponte, H.A. Serra and A. Wachs
PP193. Utilization of Drug Information Services at Komfo Anokye Teaching Hospital, Kumasi, Ghana
K. Appiah
PP194. Novel Algorithms to Identify Substandard Medicinal Products fromIndividual Case Safety Reports
K. Juhlin,G. Khodabakhshi,S.N. Pal, S. Olsson and G. Nore´n
PP195. Coding Clinical Safety Data into MedDRA: Impact on the Label
C.R. Knight
PP196. Continuation Rates, Reasons for Removal and Safety of the Levonorgestrel Intrauterine Device in New Zealand Adolescents: A Nationwide Cohort Study
H. Paterson, M. Harrison Woolrych and J. Ashton
PP197. Pharmacovigilance and ADRs Reporting Knowledge among Iranian Healthcare Professionals
K. Bayati, F. Yalchi, P. Hafez Taghva and H. Faegh
PP198. Statin Therapy and Fever in Cardiac Outpatients of Penang General Hospital of Malaysia
H.A. Abdulrazzaq, S. Syed Sulaiman, Y.W. Kassab1 and O. Ismail
PP199. Adverse Drug Reactions to Anti-Asthmatics in Patients with Bronchial Asthma
C. Kim, J. Cho, E. Jung and H. Lee
PP200. Prescription Trends for Antipsychotics in Patients with Dementia in the UK
K. Donegan, C. Davies, S. Seabroke and J. Wong
PP201. Valproic Acid-Induced Hyperammonemic Encephalopathy at Subtherapeutic Concentration
M.L. Ponte, C. Armenteros, V. Torres, N. Maddalena, S. Sosa and G. Faracce
PP202. Healthcare Professionals’ Knowledge About Pharmaceutical Excipients: Pilot Study
H.A. Abdulrazzaq,S. Syed Sulaiman, M.F. Najjar, Y.W Kassab and O. Ismail
PP203. Drug Use and Spontaneous Abortion: A Case-Control Study
D. Abadie, C. Hurault Delarue,C. Damase Michel, T. Vial ,J. Montastruc and I. Lacroix
PP204. Role of Drugs Modifying the Intra-Renal Haemodynamic in Intravenous Immunoglobulin-Induced Renal Failure: A Case-Control Study
G. Moulis, L. Sailler, A. Sommet and M. Lapeyre Mestre
PP205. Sparse Batch Number Reporting for Biologicals in FDA’s Adverse Event Reporting System (AERS)
N.S. Vermeeri, 1 S.M. Straus, A.K. Mantel Teeuwisse, T.C. Egberts, H.G. Leufkens and M.L. De Bruin
PP206. Internet and Social Media Impacts on Turkish Healthcare Professionals’ Reaching Health and Drug Side Effect-Related Information
Y. Arıkan and T. Benker
PP207. Turkish Patients’ Use of Internet and Social Media for Healthcare and Drug Side Effect Information
T. Benker and Y. Arıkan
PP208. Screening Local Medical Literature, not Accessible through Digital Databases,is Feasible and Highly Valuable in the Mining of Safety Information
N. Tsiakkas, K. Paschou, K. Krousti, G. Kolangi and Z. Athanassiou
PP209. Comparative Study of Adverse Drug Reactions Between a Public and a Private Specialist Hospital in Lagos, South West Nigeria
A. Adeniyi, I. Oreagba, I. Ishola, S. Olayemi, O. Adedeji, M. Adekoya and A. Adewunmi
PP210. Key Elements Contributing to Adverse Drug Interaction Safety Signals
J. Strandell, N.G. Nore´n and S. Hagg
PP211. Short-Term Impacts of Pharmacovigilance Education on the Pharmacovigilance Knowledge Level of Fifth-Year Medical Students
A.M. Arici, A. Gelal, Y. Demiral and Y. Tuncok
PP212. Validating a Trigger Tool to Identify Adverse Drug Events Using Electronic Prescription Records: An Example Using Two Triggers in a UK Setting
U. Nwulu, R. Odesanya,S.E. McDowell and J.J. Coleman
PP213. Early Adopters of Accredited Course in Pharmacovigilance
D. Layton, L. Harvey and S.A. Shakir
PP214. Nocturnal Enuresis in a Child Associated with Valproic Acid
A. Zaiem, I. Aouinti, G. Lakhoua, R. Daghfous, M. Lakhal and S. El Aidli
PP215. Adverse Reactions Associated with Quinolones
A. Zaiem, I. Aouinti, G. Lakhoua, S. Kastalli, R. Daghfous, M. Lakhal and S. El Aidli
PP216. Attitudes and Knowledge of Community Pharmacy Professionals to Adverse Drug Reaction Reporting in Coimbra, Portugal
C.F. Matos, J.J. Joaquim and T.S. Pires
PP217. Comparative Assessment of Adverse Reaction Reports Submitted to WHO-UMC by the Turkish Pharmacovigilance Center (TUFAM) through 2008/2009/2010
E. Aykac¸, D.N. Aydınkarahaliloglu, Y. Kasap, G. Sagis¸ C. Babacanoglu, H. Ilbars, S. Kılıc¸, H.O zbek and S. Kerman
PP218. A look at the Past: History of Rimonabant
D.N. Aydinkarahaliloglu,E. Aykac¸, Y. Kasap, G. Sagis ,C. Babacanoglu, H. Ilbars, B.O. Yıldız , S. Sardas¸ ,H. Ozbek and S. Kerman
PP219. Education and Training Activities of TUFAM
D. Aydinkarahaliloglu, E. Aykac¸, Y. Kasap, G. Sagis¸ C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP220. Turkish Pharmacovigilance Center (TUFAM) and Monitoring of Safety Warnings
Y. Kasap, D.N. Aydınkarahaliloglu, E. Aykac¸, G. Sagis, C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP221. Drugs Recalled from the Market and Given Black-Box Warning Due to Safety Issues in Turkey
D.N. Aydinkarahaliloglu, E. Aykac¸, Y. Kasap, G. Sagis, C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP222. Suicidality and Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenalin Reuptake Inhibitors: Analysis of the French Pharmacovigilance Database
S. Tan, C. Le Beller, F. Coudore´, P. Auriche and A. Lillo Le Louet
PP223. Necessity to Implement Pharmacovigilance of Medicinal Plants in
Sub-Saharan African Countries
R.K. Cimanga, N.K. Ngombe, T.M. Nanga, G.K. Mesia and G.L. Tona
PP224. Our 6 Years of Local Experience in Pharmacovigilance
E. Arda, F. Gezerler and S. Altug
PP225. Evaluation of Drug License Suspensions and Withdrawals between 1999 and 2010
E. Can
PP226. Safety Profile of Indacaterol: Results of an Early Experience Program in Mexico
G.A. Barrera and M.D. Fuentes
PP227. The Assessment of Knowledge/Attitude of Community Pharmacists Located in Istanbul towards New Pharmacovigilance Regulations
G.C. Askın, N.P. Ay, G.Z. Omurtag and S. Sardas
PP228. Metamizole (Dipyrone) and Agranulocytosis in Germany: Long-Term consequences of a Regulatory Measure in 1986
T. Stammschulte and U. Gundert Remy
PP229. Attitude and Awareness of ADR Reporting by Hospital Health Professionals in the Holy City of Makkah, Kingdom of Saudi Arabia (KSA)
N.N. Alhazmi
PP230. Community Pharmacists’ Attitude and Willingness Towards the Reporting of Adverse Drug Reactions in Bulgaria
V. Stoynova and I. Getov
PP231. Psychiatric and Behaviour-Related Adverse Events Occurring with Antiasthmatic Drugs Reported in the National Pharmacovigilance Network
F. Trotta, L. Tartaglia, F. Ferrazin and C. Santuccio
PP232. Analysis of Spontaneous Adverse Drug Reaction (ADR) Reports from the Yellow Card Scheme (YCS) in 2010
M.M. Jadeja, S. Suri, M. Foy, S. Gandhi and S. Cumber
PP233. One in Three Adverse Reactions Induced byTopical Antiglaucoma Medications is Systemic: Analysis of Adverse Drug Reactions Spontaneously Reported to Croatian Agency for Medicinal Products and Medical Devices
M. Banovac, A. Andric, V. Macolic Sarinic, N. Mirosevic Skvrce and S. Tomic
PP234. Hospital Admissions Caused by Suspected Adverse Drug Reactions (ADRs) in a Hospital Clinical Medicine Unit in Co´rdoba, Argentina
R. Herrera Comoglio, L. Alesso, G. Carelli , M. Garrido and C. Nota
PP235. Emergency Department Visits Caused by Adverse Drug Reactions: Results of a Turkish University Hospital
M.C. Girgin, S. Yanturali, A.M. Arici , N. Colak Oray, O. Doylan, Y. Demiral and Y. Tuncok
PP236. To Centralise or Not to CentraliseyThat is the Question: A Pilot Project Analysis of Regional Pharmacovigilance Centres in the Czech Republic
V. Descikova and J. Mlada
PP237. Adverse Events Induced by Oral Contraceptives: A Review on Reported Cases to a National Pharmacovigilance Centre
N. Javidnikou and G. Shalviri
PP238. Reports Submitted to WHO-UMC by TUFAM through 2008/2009/2010:
Elaborated Assessment of Adverse Reactions in Pediatric Population
E. Aykac¸, D.N. Aydınkarahaliloglu, Y. Kasap, G. Sagis ,C. Babacanoglu, H. Ilbars, H. Ozbek and S. Kerman
PP239. Literature Reports Submitted to Turkish Pharmacovigilance Center (TUFAM) by Authorization Holders in 2010
G. Sagis¸ , C. Babacanoglu, D.N. Aydınkarahaliloglu, E. Aykac,Y. Kasap, H. Ilbars, H. Ozbek and S. Kerman
PP240. Place of Imatinib Plasmatic Level in the Management of Cutaneous Side Effects Induced by Imatinib (Glivec_): Two Cases Studies
E. Gaies, S. Trabelsi, S. Srairi, I. Salouage, R. Charfi, N. Jebabli, R. Daghfous, M. Lakhal and A. Klouz
PP241. Activity of Pharmacovigilance Unit of Ibn Rochd University Hospital for 2010 (Kingdom of Morocco)
A. Elrherbi, A. Meftah, M.E. Elkarimi, I. Rahmoun, D. M’zah, H. Filali, A. Tazi and F. Hakkou
PP242. Cerebral Hemorrhages with Vitamin K Antagonists: A Prospective Study Over 5 Years in a French Neurosurgical Unit
G. Maura, E. Sole´, E. Herlem, M. Germain and T. Trenque
PP243. Lidocaine-Induced Neurotoxicity: A Case Report
E. Gaies, N. Jebabli, S. Trabelsi, I. Salouage, R. Charfi, M. Lakhal and A. Klouz
PP244 Comparison of Knowledge, Attitude, and Practices of Doctors and Nurses on Adverse Drug Reaction Monitoring and Reporting in a Tertiary Care Hospital (not in the abstract book)
H S Rehan, YK Gupta, R Sah, and D Chopra
